Bromofosfamide
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577819

CAS#: 104149-14-6

Description: Bromofosfamide, alkso known KM-135, is an alkylating agent with antitumor activity.

Chemical Structure

img
Bromofosfamide
CAS# 104149-14-6
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 577819
Name: Bromofosfamide
CAS#: 104149-14-6
Chemical Formula: C7H15BrClN2O2P
Exact Mass: 303.97
Molecular Weight: 305.540
Elemental Analysis: C, 27.52; H, 4.95; Br, 26.15; Cl, 11.60; N, 9.17; O, 10.47; P, 10.14

Price and Availability

Size Price Availability Quantity
5mg USD 150 Ready to Ship
10mg USD 250 Ready to Ship
25mg USD 450 Ready to Ship
50mg USD 750 Ready to Ship
100mg USD 1350 Ready to Ship
Bulk inquiry

Synonym: Bromofosfamide; KM 135; KM-135; KM135;

IUPAC/Chemical Name: 2-((2-bromoethyl)amino)-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide

InChi Key: ZJVAVRRLTFVZIP-UHFFFAOYSA-N

InChi Code: InChI=1S/C7H15BrClN2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)

SMILES Code: C1CN(P(=O)(OC1)NCCBr)CCCl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Bromofosfamide, also known KM-135, is an alkylating agent with antitumor activity.
In vitro activity: Combination of CY or CBM-11 with 6-7 p.t. injections of IL-2-secreting cells resulted in potentiation of the therapeutic effects: TGD and ILS values were considerably increased and long-lasting CRs were observed. The overall incidence of CR after combined treatment was ca 16% and 42% for CY and CBM-11, respectively (P=0.049). Reference: Med Oncol. 1999 Dec;16(4):267-78. https://pubmed.ncbi.nlm.nih.gov/10618690/
In vivo activity: (S)-(-)-Bromofosfamide (CBM-11), an enantiomerically pure bromo analog of ifosfamide, was found to be potent against several model tumors in mice. Therapeutic indices of CBM-11 were more favorable as compared to those received for ifosfamide. Reference: Anticancer Drugs. 2001 Jun;12(5):453-8. https://pubmed.ncbi.nlm.nih.gov/11505792/

Preparing Stock Solutions

The following data is based on the product molecular weight 305.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med Oncol. 1999 Dec;16(4):267-78. doi: 10.1007/BF02785873. PMID: 10618690. 2. Misiura K, Kinas RW, Kuśnierczyk H, Radzikowski C, Stec WJ. (S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice. Anticancer Drugs. 2001 Jun;12(5):453-8. doi: 10.1097/00001813-200106000-00006. PMID: 11395573.
In vitro protocol: 1. Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med Oncol. 1999 Dec;16(4):267-78. doi: 10.1007/BF02785873. PMID: 10618690.
In vivo protocol: 1. Misiura K, Kinas RW, Kuśnierczyk H, Radzikowski C, Stec WJ. (S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice. Anticancer Drugs. 2001 Jun;12(5):453-8. doi: 10.1097/00001813-200106000-00006. PMID: 11395573.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Liang J, Huang M, Duan W, Yu XQ, Zhou S. Design of new oxazaphosphorine anticancer drugs. Curr Pharm Des. 2007;13(9):963-78. doi: 10.2174/138161207780414296. PMID: 17430192.


2: Misiura K. Leki oksazafosforinanowe. Poszukiwanie nowych pochodnych, badania metabolizmu i stosowanie nowych strategii terapeutycznych terapeutycznych [Oxazaphosphorinane drugs. New analogues, metabolic studies, and therapeutic approaches]. Postepy Hig Med Dosw (Online). 2004;58:463-71. Polish. PMID: 15599340.


3: Misiura K. Synthesis of potential metabolites of (S)-(-)-bromofosfamide. Pharmazie. 2004 Sep;59(9):668-72. PMID: 15497745.


4: Kobylińska K, Koralewski P, Sobik B, Gasiorek M, Kobylińska M. Pharmacokinetics and toxicity of oral (-)-(S)-bromofosfamide in lung cancer patients. Arzneimittelforschung. 2001;51(7):600-3. doi: 10.1055/s-0031-1300086. PMID: 11505793.


5: Kobylińska K, Kobylińska M, Sobik B. Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice. Arzneimittelforschung. 2001;51(7):596-9. doi: 10.1055/s-0031-1300085. PMID: 11505792.


6: Misiura K, Kinas RW, Kuśnierczyk H, Radzikowski C, Stec WJ. (S)-(-)-Bromofosfamide (CBM-11): synthesis and antitumor activity and toxicity in mice. Anticancer Drugs. 2001 Jun;12(5):453-8. doi: 10.1097/00001813-200106000-00006. PMID: 11395573.


7: Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med Oncol. 1999 Dec;16(4):267-78. doi: 10.1007/BF02785873. PMID: 10618690.


8: Sloderbach A, Hładoń B, Sochacki M, Kinas R, Kuśnierczyk H, Laskowska H. Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide. Pol J Pharmacol. 1997 Nov-Dec;49(6):463-9. PMID: 9566050.


9: Kuśnierczyk H, Konarski L, Kowalski P, Radzikowski C. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. Arch Immunol Ther Exp (Warsz). 1997;45(1):79-85. PMID: 9090445.


10: Sloderbach A, Hładoń B, Laskowska H. Pharmacokinetics and bioavailability of stereoisomeric analogues of ifosfamide. Acta Physiol Hung. 1996;84(4):459-60. PMID: 9328631.


11: Studzian K, Kinas R, Ciesielska E, Szmigiero L. Effects of alkylating metabolites of ifosfamide and its bromo analogues on DNA of HeLa cells. Biochem Pharmacol. 1992 Mar 3;43(5):937-43. doi: 10.1016/0006-2952(92)90596-b. PMID: 1554391.